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Sirs,
In a recent edition of Pediatric Nephrology, we reported the
case of a child with a slowly progressive on-going atypical
hemolytic uremic syndrome (aHUS) associated with a
mutation in the gene encoding membrane cofactor protein
(CD46) [1]. Mutation screening of CFH, CFI, C3 and CFB
showed no abnormalities. Serum factor H and factor I
concentrations were 0.55 g/l (normal range 0.35–0.59 g/l)
and 49 mg/l (normal range 38–58 mg/l), respectively.
Mutation screening of CD46 showed a heterozygous
missense mutation in exon 11 (c.1058C > T, p.Ala353Val;
alternative syntax Ala304Val). The course of this child
contrasted with the often observed repetition of acute HUS
episodes generally followed by complete recovery of renal
function that is presented by most patients with a CD46
mutation [2]. The initial episode was treated with daily
plasma exchanges (PE). Although this treatment was
initially associated with a complete renal function recovery,
over the next 4 years there was a progressive decline in
renal function to end-stage renal failure (ESRF) despite
prophylactic PEs, with evidence of an on-going thrombotic
microangiopathy seen at kidney biopsy. Seventeen
months after starting hemodialysis, the patient received a
cadaver kidney transplant. Immunosuppression comprised
prednisolone, low-dose cyclosporine, mycophenolate
mofetil and basiliximab. Plasma therapy was undertaken
immediately prior to transplantation, was continued daily
during the first postoperative week and was then stopped.
The HUS did not recur, and the plasma creatinine level
24 months post-transplant was 0.9 mg/dL (80 μmol/L).
From that time onwards, the patient developed a progres-
sive fatigue, polypnea and hypoxia without any clinical or
laboratory sign of HUS recurrence. No infectious etiology
was found. Ultrasound of the heart led to a diagnosis of
pulmonary hypertension. The chest X-ray showed diffuse
increased vascular prints. The first of the two high-
resolution computed tomography scans of the lung that
were performed led to a suspicion of embolism in one
pulmonary artery, but this diagnosis could not be confirmed
in subsequent tests. The patient was transferred to the
University of Groningen for further diagnostic investiga-
tions and was placed on the waiting list for lung
transplantation. Due to rapid worsening of hypoxia despite
maximal oxygen administration and sildenafil treatment,
the patient expired from cardio-respiratory insufficiency.
Necropsy analysis of the lungs showed a massive endothelial
proliferation in post-capillary venules, strongly indicating a
diagnosis of pulmonary veno-occlusive disease (PVOD).
Etiological investigation of a suspected pulmonary embolism
led to the finding of hyperhomocysteinanemia (plasma
concentration: 185 μg/L). Subsequent DNA sequence analy-
sis of the methylmalonic aciduria cblC with homocystinuria
type C gene (MMACH, NM_015506.2) revealed two
heterozygous variants: c.276G > T; p.(Glu92Asp)/erroneous
splicing and c.442_444delinsA; p.(Val148MetfsX33). The
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c.276G > T represents the last base of an exon, and the
mutation is thus predicted to cause erroneous splicing, as
indeed indicated by several splice prediction tools (e.g.
http://www.fruitfly.org/seq_tools/splice.html). To the best of
our knowledge, both variants are novel and should be
considered pathogenic due to their nature of the mutation
(frameshift/erroneous splicing). Moreover, the variants were
not detected in 210 control alleles. DNA sequence analysis
of the parents confirmed compound heterozygosity in the
affected child. Several mutations corresponding to different
subgroups of Cbl (cobalamin) disorders have been identified.
Depending on the subgroup, there may be a processing
defect in either the remethylation of homocysteine to
methionine or the conversion of L-methylmalonyl-CoA to
succinate, or in both mechanisms, leading to hyperhomocys-
teinemia, methylmalonylaminoacidemia or the association of
both metabolic abnormalities, respectively. It should be
noted that the cblC disorder is the most common inborn
error of Cbl metabolism. Several cases of aHUS associated
with cobalamin disorders have already been reported, and
these were recently reviewed in Pediatric Nephrology [3].
Two different types of cblC MMACHC gene mutations
leading to early (neonatal) and late onset aHUS (as in our
patient), respectively, have been described (for review, see
[3]).
The unusual course of renal function for aHUS associ-
ated with CD46 mutations observed in this patient confirms
previous observations suggesting that the latter lead to
ESRF only in presence of genetic and/or environmental
modifiers of disease expression, such as combined muta-
tions [2].
Hyperhomocysteinemia-induced damage to glomerular
endothelium has been suggested as the putative mechanism
for cblC-associated HUS [3, 4] . Homocysteine alters the
antithrombotic properties of the vascular endothelium,
possibly through impairing the nitric oxide-mediated
inhibition of platelet aggregation [4]. In our patient, the
already intrinsically fragile membrane of the endothelial
cells resulting from the CD46 mutation was exposed to the
toxicity of high plasma concentrations of homocysteine
resulting from the MMACHC gene mutations. The lack of
HUS recurrence after transplantation confirms the role of
the interaction of both mechanisms on the glomerular
endothelium since the transplanted kidney most likely did
not present any CD46 mutation. Following kidney trans-
plantation, the anti-calcineurin endothelial toxicity of
cyclosporine may have been the ultimate triggering factor
for endothelial cell proliferation in pulmonary venules.
In conclusion, this case report suggests that the progres-
sive on-going HUS leading to ESRF as well as the fatal
PVOD observed in this patient probably resulted from the
combination of different pathogenic mechanisms of endo-
thelial dysfunction associated with CD46 and cblC
MMACHC gene mutations. It clearly indicates that, in
addition to performing mutation analyses for genes coding
for complement factors and antibodies directed against the
latter, investigations aimed at identifying Cbl disorders via
homocysteine and methylmalonic acid determination and
mutation analyses should be added to the work-up of every
aHUS case whatever the age of presentation of the patient
since clinical manifestations can be delayed and the latter
diagnosis may have important clinical and therapeutic
implications.
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